Batroxobin API Manufacturers

General Description:

Batroxobin, identified by CAS number 9039-61-6, is a notable compound with significant therapeutic applications. Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. The MW of batroxobin is approximately 43,000 g/mol-1, and it contains 231 amino acids. Batroxobin is inactivated by alpha2-macroglobulin, but not anti-thrombin compounds. Batroxobin will also bind fibrinogen in a manner different than thrombin and with a higher affinity. Once bound to fibrin, it will cause fibrin accretion(clot formation) to a degree 18 folds greater than thrombin. Currently use is experimental but trials have been conducted which support certain clinical applications. Recombinant Batroxobin in relatively affordable and could be accessed by mass production.

Indications:

This drug is primarily indicated for: No approved indications. Batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Pharmacodynamics:

Batroxobin exerts its therapeutic effects through: Insensitive to thrombin inhibitors and capable of clotting platelet rich plasma without affecting platelet function. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Batroxobin functions by: Batroxobin is a thrombin like serine protease enzyme that will cleave fibrinogen. Cleavage at the16 Arginine - 17 Glycine bond in the A alpha chain of fibrinogen releases fibrinopeptide A and forms a fibrin I monomer that will spontaneously aggregate into a clot. The reduction of plasma fibrinogen by formation of fibrin microclots that are easily cleared by the reticuloendothelial system can decrease high blood viscosity which contributes to the formation of thromboemboli. In addition, batroxobin is reported to induce fibrinolysis by inducing the endothelial release of tissue plasminogen activator (tPA) from vascular endothelial cells. This effect may potentially be dose dependant. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Classification:

Batroxobin belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.

Categories:

Batroxobin is categorized under the following therapeutic classes: Biological Factors, Blood and Blood Forming Organs, Cardiovascular Agents, Coagulants, Complex Mixtures, Crotalid Venoms, Endopeptidases, Enzymes, Enzymes and Coenzymes, Fibrin Modulating Agents, Hematologic Agents, Hemostatics, Hydrolases, Peptide Hydrolases, Serine Endopeptidases, Serine Proteases, Snake Venoms, Toxins, Biological, Venombin A, Venoms, Viper Venoms. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.